Compare The Coca-Cola Co K (KO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Regeneron Pharmaceuticals Inc — how do they compare? The Coca-Cola Co K trades at $86.5 (market cap $373.76B), while Regeneron Pharmaceuticals Inc trades at $799 (market cap $83.19B). The key difference: The Coca-Cola Co K is far larger — about 4.5× Regeneron Pharmaceuticals Inc's market cap, and The Coca-Cola Co K pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| KO | REGN | |
|---|---|---|
Market Cap | $373.76B | $83.19B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $812.27 |
52-Week Low | $65.67 | $545.94 |
Enterprise Value | $400.93B | $77.90B |
Dividend Yield | 2.44% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal supported by moving averages and RSI near oversold levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats, while analyst consensus is a Buy with a $95.83 price target. Recent news highlights institutional accumulation and stable dividend trends.
The outlook remains positive given earnings momentum and dividend reliability, though risks include regional demand divergence and high valuation multiples. Upside is supported by analyst targets and institutional confidence, but investors should weigh debt levels and competitive pressures in the beverage sector.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
